Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Bismuth-212 bismuth

Synonyms: AC1O3RNC, 212Bi, 14913-49-6, Bismuth, isotope of mass 212

Rotmensch, J. et al., Macklis, R.M. et al., Kozak, R.W. et al., Macklis, R.M. et al., Kozak, R.W. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of bismuth

In this study, we asked whether Pseudomonas exotoxin or bismuth-212 (an alpha-particle emitting radionuclide) coupled to the anti-IL-2 receptor mAb, anti-Tac, were able to selectively eliminate alloresponsive cells generated during an allogeneic mixed lymphocyte reaction [1].
OBJECTIVE: Our objective was to develop the alpha-emitting radionuclide bismuth 212 for possible intraperitoneal use against microscopic ovarian cancer [2].
The distribution, toxicity, and maximum tolerated dose of bismuth 212 were determined after intraperitoneal administration in animal models [2].

High impact information on bismuth

An alpha-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared [3].
This report reviews the synthesis, testing and use in animal models of an alpha particle emitting radioimmunoconjugate constructed via the noncovalent chelation of Bismuth-212 to a monoclonal IgM antibody specific for the murine T cells/neuroectodermal surface antigen, Thy 1 [4].
In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma [2].

Analytical, diagnostic and therapeutic context of bismuth

Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy [5].

References

Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. Kozak, R.W., Fitzgerald, D.P., Atcher, R.W., Goldman, C.K., Nelson, D.L., Gansow, O.A., Pastan, I., Waldmann, T.A. J. Immunol. (1990) [Pubmed]
In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma. Rotmensch, J., Whitlock, J.L., Schwartz, J.L., Hines, J.J., Reba, R.C., Harper, P.V. Am. J. Obstet. Gynecol. (1997) [Pubmed]
Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Macklis, R.M., Kinsey, B.M., Kassis, A.I., Ferrara, J.L., Atcher, R.W., Hines, J.J., Coleman, C.N., Adelstein, S.J., Burakoff, S.J. Science (1988) [Pubmed]
Alpha particle radio-immunotherapy: animal models and clinical prospects. Macklis, R.M., Kaplan, W.D., Ferrara, J.L., Atcher, R.W., Hines, J.J., Burakoff, S.J., Coleman, C.N. Int. J. Radiat. Oncol. Biol. Phys. (1989) [Pubmed]
Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Kozak, R.W., Atcher, R.W., Gansow, O.A., Friedman, A.M., Hines, J.J., Waldmann, T.A. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.